Induction and Maintenance Strategies for Lupus Nephritis

Induction Therapy

• Glucocorticoids combined with mycophenolate mofetil (MMF) 2–3 g/day or cyclophosphamide constitute the standard induction regimen; MMF is preferred for most patients because it offers comparable efficacy with a superior safety profile, especially regarding gonadal toxicity. 1 (strong recommendation, high certainty)

• High‑dose glucocorticoids are the foundation of induction therapy for all patients with active lupus nephritis. 1 (strong recommendation, high certainty)

• MMF 2–3 g/day (or equivalent mycophenolic acid) is the first‑line immunosuppressant for Class III/IV lupus nephritis. 1 (strong recommendation, high certainty)

• MMF demonstrates efficacy at least equal to cyclophosphamide while causing fewer adverse events, particularly less gonadal toxicity. 2, 3, 4 (moderate certainty)

• Tacrolimus may be used as an alternative induction agent, but the supporting evidence derives mainly from Asian cohorts. 1 (low certainty)

• Low‑dose intravenous cyclophosphamide (Euro‑Lupus regimen: 500 mg every 2 weeks for 6 doses) is recommended when cyclophosphamide is required, to limit gonadal toxicity. 1 (moderate certainty)

• High‑dose intermittent cyclophosphamide pulse therapy shows a more favorable efficacy‑to‑toxicity ratio than oral cyclophosphamide. 2, 3 (moderate certainty)

• If a significant clinical response (improved serum creatinine and proteinuria < 1 g/day) is not achieved by 6 months, therapy should be intensified. 2, 3, 4 (strong recommendation, moderate certainty)

Maintenance Therapy

• MMF or azathioprine should replace cyclophosphamide for maintenance to minimize long‑term toxicity while preventing relapses. 1 (strong recommendation, high certainty of fewer adverse events; low certainty of superior efficacy)

• MMF is preferred for patients who cannot tolerate azathioprine or who experience disease flares while on azathioprine. 2, 3, 4 (moderate certainty)

• Maintenance therapy is typically continued for 18 months to 4 years, combined with low‑dose glucocorticoids (< 7.5 mg/day) to sustain remission. (guideline consensus, not directly cited)

Immunologic Monitoring

• Low complement levels (C3, C4) correlate with active disease and predict the development of lupus nephritis. 2 (moderate certainty)

• Serial changes in anti‑dsDNA antibodies and complement have limited ability to predict treatment response and should be used only as supplemental information. 2, 5 (low certainty)

• Do not rely solely on anti‑dsDNA or complement levels to guide therapeutic decisions, because their predictive value for response is limited. 2, 5 (strong recommendation, moderate certainty)

Kidney Biopsy

• Kidney biopsy is indicated in any SLE patient with proteinuria ≥ 0.5 g/24 h (or ≥ 500 mg/g UPCR) and provides ISN/RPS histologic class, activity and chronicity indices, and helps exclude alternative diagnoses. 4 (strong recommendation, high certainty)

Special Populations

Pregnancy

• Medications considered safe in pregnancy include prednisolone (and other non‑fluorinated glucocorticoids), azathioprine, hydroxychloroquine, and low‑dose aspirin. 3, 5, 4 (moderate certainty)

• Mycophenolate mofetil, cyclophosphamide, and methotrexate are contraindicated during pregnancy. 3, 5, 4 (strong recommendation, high certainty)

• Lupus nephritis patients with antiphospholipid antibodies have a higher risk of pre‑eclampsia and require closer obstetric monitoring. 5 (moderate certainty)

• Combined unfractionated or low‑molecular‑weight heparin plus low‑dose aspirin reduces pregnancy loss and thrombosis in women with antiphospholipid syndrome. 5 (moderate certainty)

Childhood‑Onset Lupus Nephritis

• Induction therapy in children uses high‑dose glucocorticoids (prednisone 1–2 mg/kg/day, max 60 mg/day) together with MMF or cyclophosphamide. 1 (moderate certainty)

• For maintenance, MMF or azathioprine is preferred over cyclophosphamide; azathioprine may be favored in resource‑limited settings. 1 (moderate certainty)

• Pharmacokinetic differences in children may require higher MMF dosing to achieve therapeutic exposure. 1 (low certainty)

Refractory Disease

• Rituximab (375 mg/m² IV weekly for 4 weeks) can be considered for refractory lupus nephritis; small trials suggest up to 50 % response in patients who failed cyclophosphamide. 2, 3, 4 (low certainty)

Safety and Pitfalls

• Do not continue cyclophosphamide for maintenance when MMF or azathioprine are available, due to cumulative toxicity. 1 (strong recommendation, high certainty)

• Avoid indiscriminate use of NSAIDs in lupus nephritis because of added nephrotoxic risk. 5 (strong recommendation, moderate certainty)

• Do not use mycophenolate mofetil, cyclophosphamide, or methotrexate during pregnancy. 3, 5, 4 (strong recommendation, high certainty)

Diagnosis and Management of Lupus Nephritis

Initial Clinical Assessment

• The American College of Rheumatology recommends that all patients with SLE should undergo routine screening for lupus nephritis with urinalysis, urine protein-to-creatinine ratio (UPCR), serum creatinine, and blood pressure at every visit 6
• Urinalysis with microscopy is essential to assess for proteinuria, hematuria, cellular casts, and pyuria, with red blood cell casts being highly specific for glomerulonephritis 6, 7
• Quantifying proteinuria through 24-hour urine collection or spot UPCR is crucial, with the latter being preferred for convenience 6, 8
• Serum creatinine and eGFR should be established to determine baseline kidney function and detect acute changes 6, 7
• Complete blood count is necessary to evaluate for cytopenias, which associate with disease activity and infection risk 6
• Serum albumin levels should be measured, as low levels indicate nephrotic syndrome and provide prognostic information 6

Immunologic Workup

• The European League Against Rheumatism recommends assessing anti-dsDNA antibodies, which are associated with lupus nephritis activity, though they have limited predictive value for treatment response 6, 9
• Complement levels (C3, C4) should be measured, as low levels correlate with active disease and predict lupus nephritis 6, 9
• Antiphospholipid antibodies are essential for assessing thrombosis risk and pregnancy complications 6, 9, 10

Kidney Biopsy Indications

• The American College of Rheumatology recommends that kidney biopsy is essential for any SLE patient with proteinuria ≥0.5 g/24h (or ≥500 mg/g UPCR) with or without hematuria, cellular casts, or unexplained decline in kidney function 7
• Kidney biopsy provides critical information, including ISN/RPS histologic class, activity and chronicity indices, and excludes alternative diagnoses 7, 10

Additional Diagnostic Considerations

• When lupus nephritis is suspected with concurrent thrombocytopenia and microangiopathic hemolytic anemia, ADAMTS13 activity and antibodies should be measured to distinguish thrombotic thrombocytopenic purpura 10
• The PLASMIC score should be calculated to risk-stratify for TTP 10
• Antiphospholipid antibodies should be measured to identify antiphospholipid syndrome-associated TMA 10
• Initiation of plasma exchange and glucocorticoids is recommended while awaiting results in adults with high clinical suspicion 10

Monitoring Parameters

• The American College of Rheumatology recommends that treatment response should be evaluated at 3-4 months, with expectations of ≥25% proteinuria reduction by 3 months, ≥50% reduction by 6 months, and target <0.5-0.7 g/g by 12 months 8
• Complete response is defined as proteinuria <0.5 g/g with stable/improved kidney function within 6-12 months 8, 10
• Partial response is defined as ≥50% proteinuria reduction to <3 g/g with stable kidney function within 6-12 months 8, 10
• No response is defined as failure to achieve partial or complete response by 6-12 months 8, 10
• Ongoing surveillance should include monitoring of urine sediment, UPCR, serum creatinine, and immunologic markers (anti-dsDNA, C3, C4) at each visit 6, 9